Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment

Nasopharyngeal carcinoma (NPC) is a form of head and neck cancer of multifactorial etiolo-gies that is highly prevalent among men in the population of Southern China and Southeast Asia. NPC has claimed many thousands of lives worldwide; but the low awareness of NPC remains a hindrance in early diagnosis and prevention of the disease. NPC is highly responsive to radiotherapy and chemothera-py, but radiocurable NPC is still dependent on concurrent treatment of megavoltage radiotherapy with chemotherapy. Despite a significant reduction in loco-regional and distant metastases, radiotherapy alone has failed to provide a significant improvement in the overall survival rate of NPC, compared to chemo-therapy. In addition, chemo-resistance persists as the major challenge in the management of metastatic NPC although the survival rate of advanced metastatic NPC has significantly improved with the admin-istration of chemotherapy adjunctive to radiotherapy. In this regard, targeted molecular therapy could be explored for the discovery of alternative NPC therapies. Nutlin-3, a small molecule inhibitor that specifi-cally targets p53-Mdm2 interaction offers new therapeutic opportunities by enhancing cancer cell growth arrest and apoptosis through the restoration of the p53-mediated tumor suppression pathway while pro-ducing minimal cytotoxicity and side effects. This review discusses the potential use of Nutlin-3 as a p53-activating drug and the future directions of its clinical research for NPC treatment.

[1]  Jin-Ching Lin,et al.  Current management of nasopharyngeal cancer. , 2012, Seminars in radiation oncology.

[2]  A. Arbor,et al.  p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells , 2011, Leukemia.

[3]  Pankaj Oberoi,et al.  Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. , 2005, Cancer cell.

[4]  P. Xia,et al.  Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. , 2000, International journal of radiation oncology, biology, physics.

[5]  Chien-Jen Chen,et al.  Cigarette smoking, alcohol consumption and risk of nasopharyngeal carcinoma in Taiwan , 2004, Cancer Causes & Control.

[6]  F. Speleman,et al.  Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. , 2009, Journal of the National Cancer Institute.

[7]  Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts. , 2011, Cancer letters.

[8]  Jacques Ferlay,et al.  GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 , 2013 .

[9]  D. Parks,et al.  Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo , 2006, Molecular Cancer Therapeutics.

[10]  G. Juliusson,et al.  Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Y. F. Poon,et al.  Establishment of a cell line (NPC/HK1) from a differentiated squamous carcinoma of the nasopharynx , 1980, International journal of cancer.

[12]  Y. Tabuchi,et al.  Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells. , 2010, Cancer letters.

[13]  Akira Endou,et al.  Effect of Y220C Mutation on p53 and Its Rescue Mechanism: A Computer Chemistry Approach , 2013, The Protein Journal.

[14]  C. J. Chen,et al.  Occupational exposure to wood, formaldehyde, and solvents and risk of nasopharyngeal carcinoma. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[15]  I. Chitapanarux,et al.  Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. , 2007, European journal of cancer.

[16]  D. Helfman,et al.  Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53 , 1985, Molecular and cellular biology.

[17]  S. Laín,et al.  Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs , 2011, Oncotarget.

[18]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[19]  宮地 充.  Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells , 2010 .

[20]  A. Weinberg,et al.  Nutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin-2 in Kaposi sarcoma tumor cells , 2012, Cell cycle.

[21]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.

[22]  Marina Konopleva,et al.  MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. , 2005, Blood.

[23]  Jian-Min Yuan,et al.  Preserved foods in relation to risk of nasopharyngeal carcinoma in Shanghai, China , 2000, International journal of cancer.

[24]  J. Niland,et al.  The MDM2 gene amplification database. , 1998, Nucleic acids research.

[25]  J. Beck,et al.  Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells. , 2011, European journal of cancer.

[26]  E. White,et al.  Nutlin-3 Protects Kidney Cells during Cisplatin Therapy by Suppressing Bax/Bak Activation* , 2007, Journal of Biological Chemistry.

[27]  S. Ogawa,et al.  The genomic landscape of nasopharyngeal carcinoma , 2014, Nature Genetics.

[28]  C. Koh,et al.  Mitosis-targeted anti-cancer therapies: where they stand , 2012, Cell Death and Disease.

[29]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[30]  S. K. Subramaniam,et al.  Nasopharyngeal Carcinoma Database. , 2008, The Medical journal of Malaysia.

[31]  J. Schleper.  Prevention, detection, and diagnosis of head and neck cancers. , 1989, Seminars in oncology nursing.

[32]  Hongbo Wang,et al.  A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells. , 2011, Neoplasia.

[33]  C. Snyderman,et al.  Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. , 1989, Cancer research.

[34]  I. Tham,et al.  Late toxicities after conventional radiation therapy alone for nasopharyngeal carcinoma. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[35]  K. Wiman,et al.  Reactivation of mutant p53: molecular mechanisms and therapeutic potential , 2007, Oncogene.

[36]  J. Herman,et al.  Adulthood consumption of preserved and nonpreserved vegetables and the risk of nasopharyngeal carcinoma: A systematic review , 2006, International journal of cancer.

[37]  Frei E rd,et al.  Phase I and phototoxicity studies of pseudourea (NSC-56054). , 1971 .

[38]  L. You,et al.  Nasopharyngeal carcinoma—Review of the molecular mechanisms of tumorigenesis , 2008, Head & neck.

[39]  P. Ouillette,et al.  Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. , 2010, Blood.

[40]  H. Mai,et al.  Emerging treatment options for nasopharyngeal carcinoma , 2013, Drug design, development and therapy.

[41]  D. Lane,et al.  Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity , 2015, Oncology reports.

[42]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[43]  P. Xia,et al.  Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. , 2001, International journal of radiation oncology, biology, physics.

[44]  Y. Pommier,et al.  Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2 , 2008, Molecular Cancer Therapeutics.

[45]  O. Myklebost,et al.  Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin‐3A , 2007, International journal of cancer.

[46]  B. Henderson,et al.  Cantonese-style salted fish as a cause of nasopharyngeal carcinoma: report of a case-control study in Hong Kong. , 1986, Cancer research.

[47]  Xiang Guo,et al.  Endoscopic microwave coagulation therapy for early recurrent T1 nasopharyngeal carcinoma. , 2009, European journal of cancer.

[48]  S. Hee,et al.  Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the national cancer centre singapore experience. , 2008, International journal of radiation oncology, biology, physics.

[49]  T. Ishida,et al.  Cytochrome P450 2A6 polymorphism in nasopharyngeal carcinoma. , 2006, Cancer letters.

[50]  F. De Vita,et al.  Anti‐epidermal growth factor receptor monoclonal antibodies in cancer therapy , 2009, Clinical and experimental immunology.

[51]  M. He,et al.  A mutant P53 can activate apoptosis through a mechanism distinct from those induced by wild type P53 , 2002, FEBS letters.

[52]  I. Witterick,et al.  Endoscopic nasopharyngectomy: Patient selection and surgical execution , 2014 .

[53]  Shaomeng Wang,et al.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. , 2009, Annual review of pharmacology and toxicology.

[54]  Alan R. Fersht,et al.  Small molecule induced reactivation of mutant p53 in cancer cells , 2013, Nucleic acids research.

[55]  Fengzhi Li,et al.  Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture , 2011, Oncotarget.

[56]  S. de Jong,et al.  Disruption of the MDM2–p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway , 2011, Cell Death and Disease.

[57]  H. Hsu,et al.  Cooperative interactions among p53, bcl‐2 and Epstein–Barr virus latent membrane protein 1 in nasopharyngeal carcinoma cells , 2004, Pathology international.

[58]  Bo Xu,et al.  Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Lee Baker,et al.  Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator , 2007, Cancer cell.

[60]  D. Zhu,et al.  [A hot-spot mutation of p53 gene in nasopharyngeal carcinoma]. , 1995, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[61]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.

[62]  K. Kinzler,et al.  Disruption of p53 in human cancer cells alters the responses to therapeutic agents. , 1999, The Journal of clinical investigation.

[63]  Frank M Boeckler,et al.  Targeted rescue of a destabilized mutant of p53 by an in silico screened drug , 2008, Proceedings of the National Academy of Sciences.

[64]  R. W. Armstrong,et al.  Salted fish and nasopharyngeal carcinoma in Malaysia. , 1983, Social science & medicine.

[65]  R. Mould,et al.  Nasopharyngeal carcinoma: treatments and outcomes in the 20th century. , 2002, The British journal of radiology.

[66]  Jian-Min Yuan,et al.  Epidemiology of nasopharyngeal carcinoma. , 2002, Seminars in cancer biology.

[67]  A. Khoo,et al.  Diagnosis and Clinical Evaluation of Nasopharyngeal Carcinoma , 2013 .

[68]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[69]  B. Henderson,et al.  Diet and nasopharyngeal carcinoma: A case‐control study in Guangzhou, China , 1989, International journal of cancer.

[70]  Hyobin Jeong,et al.  Mechanism of Cisplatin-Induced Cytotoxicity Is Correlated to Impaired Metabolism Due to Mitochondrial ROS Generation , 2015, PloS one.

[71]  B. O'Sullivan,et al.  Nasopharyngeal carcinoma: the next challenges. , 2010, European journal of cancer.

[72]  M. Kaminski,et al.  Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. , 2007, Blood.

[73]  A. Levine,et al.  Allele-specific p53 mutant reactivation. , 2012, Cancer cell.

[74]  K. Wiman,et al.  Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. , 2017, The Journal of Biological Chemistry.

[75]  R. Mohammad,et al.  HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas , 2012, Journal of Hematology & Oncology.

[76]  John K. Buolamwini,et al.  Therapeutic Discovery A Small-Molecule Inhibitor of MDMX Activates p 53 and Induces Apoptosis , 2011 .

[77]  W. Fee,et al.  Nasopharyngeal carcinoma: salvage of local recurrence. , 2012, Oral oncology.

[78]  D. Lane,et al.  Drugging the p53 pathway: understanding the route to clinical efficacy , 2014, Nature Reviews Drug Discovery.

[79]  L. Old,et al.  PRECIPITATING ANTIBODY IN HUMAN SERUM TO AN ANTIGEN PRESENT IN CULTURED BURKITT'S LYMPHOMA CELLS* , 1966, Proceedings of the National Academy of Sciences of the United States of America.

[80]  J. Sham,et al.  Sensorineural hearing loss in patients treated for nasopharyngeal carcinoma: a prospective study of the effect of radiation and cisplatin treatment. , 1996, International journal of radiation oncology, biology, physics.

[81]  R. Sun,et al.  A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. , 2012, Oral oncology.

[82]  K. To,et al.  Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. , 2012, Seminars in cancer biology.

[83]  D. Bashford,et al.  Identification and Characterization of the First Small Molecule Inhibitor of MDMX* , 2010, The Journal of Biological Chemistry.

[84]  Jun Ma,et al.  Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  Kai-Ping Chang,et al.  A Lack of Association Between p53 Mutations and Recurrent Nasopharyngeal Carcinomas Refractory to Radiotherapy , 2002, The Laryngoscope.

[86]  M. Rugge,et al.  p53 alteration in gastric precancerous lesions. , 1994, The American journal of pathology.

[87]  V. Grinkevich,et al.  Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. , 2010, Cell Cycle.

[88]  M. Saha,et al.  Targeting p53 by small molecules in hematological malignancies , 2013, Journal of Hematology & Oncology.

[89]  D. Lane,et al.  Cancer. p53, guardian of the genome. , 1992, Nature.

[90]  Wei Gu,et al.  p53 Activation: a case against Sir. , 2008, Cancer cell.

[91]  N. Colburn,et al.  An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[92]  A. Mills.  p63: oncogene or tumor suppressor? , 2006, Current opinion in genetics & development.

[93]  Thelma Thompson,et al.  Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization , 2012, Proceedings of the National Academy of Sciences.

[94]  D. Pim,et al.  Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. , 1984, The EMBO journal.

[95]  E. Frei,et al.  Phase I and phototoxicity studies of pseudourea (NSC-56054). , 1971, Cancer chemotherapy reports.

[96]  N. Ung,et al.  Treatment outcome for nasopharyngeal carcinoma in University Malaya Medical Centre from 2004-2008. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[97]  C. Leonetti,et al.  Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs , 2011, Cell cycle.

[98]  Yue-Cune Chang,et al.  A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. , 2002, International journal of radiation oncology, biology, physics.

[99]  John K. Buolamwini,et al.  A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis , 2010, Molecular Cancer Therapeutics.

[100]  M. Protopopova,et al.  Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors , 2004, Nature Medicine.

[101]  L. Vassilev,et al.  MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.

[102]  S. Lo,et al.  Treatment results of 1070 patients with nasopharyngeal carcinoma: An analysis of survival and failure patterns , 2005, Head & neck.

[103]  M. Andreeff,et al.  linical Development Novel Tryptamine Derivative JNJ-26854165 Induces-Type p 53-and E 2 F 1-Mediated Apoptosis in Ther te Myeloid and Lymphoid Leukemias , 2010 .

[104]  A. Chan,et al.  Pathogenesis and treatment of nasopharyngeal carcinoma. , 2004, Seminars in oncology.

[105]  S. Teo,et al.  Clinical significance of plasma Epstein-Barr Virus DNA loads in a large cohort of Malaysian patients with nasopharyngeal carcinoma. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[106]  M. Anniko,et al.  Cisplatin: evaluation of its ototoxic potential. , 1986, American journal of otolaryngology.

[107]  Jian-hua Li,et al.  Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and -negative nasopharyngeal carcinoma , 2001, Cancer Gene Therapy.

[108]  S. Peh,et al.  p53 and nasopharyngeal carcinoma: a Malaysian study , 2009, Pathology.

[109]  B. Christensson,et al.  Induction of nasal and nasopharyngeal tumours in Sprague-Dawley rats fed with Chinese salted fish. , 1994, Acta oto-laryngologica.

[110]  E. Appella,et al.  Post-translational modifications and activation of p53 by genotoxic stresses. , 2001, European journal of biochemistry.

[111]  W. Bou-Assaly,et al.  Cetuximab (Erbitux) , 2010, American Journal of Neuroradiology.

[112]  N. Day,et al.  Preserved foods and nasopharyngeal carcinoma: A case‐control study among singapore chinese , 1994, International journal of cancer.

[113]  Alan R. Fersht,et al.  Awakening guardian angels: drugging the p53 pathway , 2009, Nature Reviews Cancer.

[114]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[115]  O. Myklebost,et al.  Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[116]  A. Levine,et al.  The p53 pathway: positive and negative feedback loops , 2005, Oncogene.

[117]  T. Tursz,et al.  Alterations of the p53 gene in nasopharyngeal carcinoma , 1992, Journal of virology.

[118]  Ettore Appella,et al.  ATM Mediates Phosphorylation at Multiple p53 Sites, Including Ser46, in Response to Ionizing Radiation* , 2002, The Journal of Biological Chemistry.

[119]  L. Vassilev,et al.  Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. , 2005, Blood.

[120]  A. Fersht,et al.  Molecular mechanism of the interaction between MDM2 and p53. , 2002, Journal of molecular biology.